Two Sigma Advisers
NVO

Two Sigma Advisers’s Novo Nordisk NVO Stock Holding History

Two Sigma Advisers’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-119,600
Closed -$6.64M – 2536
2025
Q3 		$6.64M Sell
119,600
-1,272,100
-91% -$74.5M 0.01% 639
2025
Q2 		$96.1M Sell
1,391,700
-3,465,100
-71% -$236M 0.2% 109
2025
Q1 		$337M Buy
4,856,800
+3,835,100
+375% +$317M 0.76% 29
2024
Q4 		$87.9M Buy
1,021,700
+885,300
+649% +$95.7M 0.2% 93
2024
Q3 		$16.2M Sell
136,400
-22,500
-14% -$3M 0.04% 362
2024
Q2 		$22.7M Buy
158,900
+18,700
+13% +$2.48M 0.05% 304
2024
Q1 		$18M Buy
140,200
+2,400
+2% +$286K 0.04% 373
2023
Q4 		$14.3M Buy
137,800
+14,100
+11% +$1.39M 0.03% 414
2023
Q3 		$11.2M Sell
123,700
-44,700
-27% -$3.94M 0.03% 438
2023
Q2 		$13.6M Buy
168,400
+144,000
+590% +$11.8M 0.03% 402
2023
Q1 		$1.94M Sell
24,400
-6,600
-21% -$468K 0.01% 1284
2022
Q4 		$2.1M Sell
31,000
-28,000
-47% -$1.64M 0.01% 1218
2022
Q3 		$2.94M Sell
59,000
-543,800
-90% -$29.1M 0.01% 986
2022
Q2 		$33.6M Sell
602,800
-169,200
-22% -$9.39M 0.1% 226
2022
Q1 		$42.9M Sell
772,000
-581,200
-43% -$29.8M 0.11% 185
2021
Q4 		$75.8M Sell
1,353,200
-78,600
-5% -$4.26M 0.19% 118
2021
Q3 		$68.7M Buy
1,431,800
+1,110,600
+346% +$53.7M 0.18% 116
2021
Q2 		$13.5M Buy
321,200
+119,000
+59% +$4.61M 0.04% 446
2021
Q1 		$6.82M Buy
202,200
+140,800
+229% +$5.01M 0.02% 730
2020
Q4 		$2.14M Sell
61,400
-576,000
-90% -$19.9M 0.01% 1218
2020
Q3 		$22.1M Buy
637,400
+157,600
+33% +$5.25M 0.06% 295
2020
Q2 		$15.7M Buy
479,800
+330,200
+221% +$10.5M 0.05% 392
2020
Q1 		$4.5M Sell
149,600
-127,000
-46% -$3.78M 0.02% 746
2019
Q4 		$8.01M Buy
+276,600
New +$7.66M 0.02% 666
2019
Q2 		– Sell
-32,200
Closed -$842K – 2405
2019
Q1 		$842K Sell
32,200
-524,400
-94% -$12.9M ﹤0.01% 1598
2018
Q4 		$12.8M Buy
556,600
+500,800
+897% +$11.1M 0.04% 492
2018
Q3 		$1.31M Buy
+55,800
New +$1.36M ﹤0.01% 1400
2018
Q2 		– Sell
-112,000
Closed -$2.76M – 2451
2018
Q1 		$2.76M Sell
112,000
-426,200
-79% -$11.2M 0.01% 1093
2017
Q4 		$14.4M Sell
538,200
-434,400
-45% -$11M 0.04% 484
2017
Q3 		$23.4M Sell
972,600
-1,319,000
-58% -$29.8M 0.07% 325
2017
Q2 		$49.1M Sell
2,291,600
-2,085,000
-48% -$42.1M 0.16% 159
2017
Q1 		$75M Sell
4,376,600
-1,510,400
-26% -$26.3M 0.25% 104
2016
Q4 		$106M Buy
5,887,000
+5,331,360
+959% +$96.7M 0.4% 58
2016
Q3 		$11.6M Buy
+555,640
New +$13.8M 0.05% 392
2015
Q1 		– Sell
-25,240
Closed -$534K – 2248
2014
Q4 		$534K Buy
+25,240
New +$564K ﹤0.01% 1578
2013
Q4 		– Sell
-202,000
Closed -$3.42M – 2473
2013
Q3 		$3.42M Buy
+202,000
New +$3.4M 0.04% 436

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers's NVO Position: Q4 2025 in Review

Two Sigma Advisers sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 119,600 shares — an estimated $6.64M sold.

Two Sigma Advisers first reported a position in NVO in Q3 2013 and held it in 36 quarters. The position peaked at $337M in Q1 2025. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Two Sigma Advisers reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 119,600 Novo Nordisk shares in Q4 2025, an estimated $6.64M.
  • Two Sigma Advisers first reported a position in Novo Nordisk in Q3 2013 and held it in 36 quarters.
  • Two Sigma Advisers's Novo Nordisk position peaked at $337M in Q1 2025.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.